MarcoPolo Pharmaceuticals has announced results from interim analysis of the clinical study: "Double-blind, placebo-controlled clinical study to evaluate the efficacy, safety and tolerability of a fixed dose of VLB-01 as adjunctive therapy in patients with partial seizures (phase II-III)". VLB-01 has shown significant clinical and statistical results in phase II-III study in patients suffering from complex partial seizure secondary generalized or not which were not stabilized despite current antiepileptic treatment.

More...